Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

中国泰凌医药集团
CHINA NT PHARMA GROUP

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1011)

QUARTERLY UPDATES ON THE IMPLEMENTATION OF ACTION PLANS TO RESOLVE THE DISCLAIMER OF OPINION

INTRODUCTION

The board (the "**Board**") of directors (the "**Directors**") of China NT Pharma Group Company Limited (the "**Company**", together with its subsidiaries, collectively the "**Group**") hereby provides the following quarterly updates on the implementation of the Group's action plans to improve the Group's liquidity and financial position and to resolve the disclaimer of opinion (the "**Disclaimer of Opinion**") on going concern of the Company's auditor as set out in the annual report of the Company for the year ended 31 December 2025 (the "**Annual Report**"). Unless otherwise defined in this announcement, terms used herein shall have the same meanings as those used in the Annual Report.

As of the date of this announcement, the quarterly updates on the implementation of the action plans to resolve the Disclaimer of Opinion:

CORE STRATEGIC TRANSFORMATION AND BUSINESS PROGRESS

As scheduled, the Group continues to advance its strategic transformation centering on an AI-enabled Health Management Platform that covers "testing, treatment and rehabilitation" in the bone health field, and each business of the Group maintains normal operations. The Group continues to implement the layout of the bone health industry chain, consolidate the existing business foundation, promote the integration of relevant products, services and business resources, and solidify its future revenue sources, as one of the core measures to improve the Group's cash flow and financial position.

PROGRESS ON CAPITAL STRUCTURE IMPROVEMENT

Reference is made to the announcement of the Company dated 28 August 2026 in relation to the poll results of the EGM. At the EGM, the relevant resolution approving the Loan Capitalisation to offset debts of approximately HK$300 million was duly passed by the Shareholders by way of poll. Upon completion of this matter, the Group significantly reduced its scale of liabilities, and achieved noticeable improvement in its capital structure and overall financial position, thereby providing important support for the Group's subsequent going concern and strategy implementation. The Group will continue to follow up on other financial optimisation measures to continuously improve its liquidity conditions.

PROGRESS ON CONTINGENT LIABILITIES AND LEGAL PROCEEDINGS

The Company received an arbitration award rendered by the China International Economic and Trade Arbitration Commission in respect of the Miacalcic asset transaction project entered into between the Company and the relevant entities of Beijing Kangchen Biological Technology Co., Limited (北京康辰生物科技有限公司) in 2020. Upon careful assessment, the Company has significant objections to such arbitration award. The Company has engaged a compliance legal service team to initiate statutory relief procedures in accordance with the law, including applying to set aside the arbitration award.

Meanwhile, the Company has separately initiated legal proceedings, including the enforcement of shareholders' right to information, against the relevant entities of Beijing Kangchen Biological Technology Co., Limited (北京康辰生物科技有限公司).

The Board will keep close track of the progress of each of the above legal proceedings and will publish further announcement(s) as and when appropriate in accordance with the Listing Rules when there are material updates.

RISK WARNING

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
China NT Pharma Group Company Limited
Ng Tit
Chairman

Hong Kong, 30 October 2026

As at the date of this announcement, the executive Directors are Mr. Ng Tit and Ms. Ng Anna Ching Mei; the non-executive Directors are Dr. Qian Wei, Ms. Chin Yu and Mr. Lou Yongbin; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Mr. Kwok Che Chung and Dr. Zhao Yubiao.